Algernon Pharmaceuticals (CSE: AGN) is extremely undervalued based on its chronic cough drug alone. For reasons that we will explain in the upcoming days, we consider AGN's Ifenprodil to be superior to Trevi Therapeutics (TRVI)'s Haduvio, yet TRVI's market cap is currently 13X higher than AGN!
What we are most excited about is AGN's upcoming clinical trials of DMT for stroke! AGN has already developed significant DMT intellectual property and AGN's pre-clinical trials were very successful!
AGN is undiscovered as a DMT play, but the small publicly traded DMT focused start-up company Small Pharma (TSXV: DMT) is up another 22% today alone and now has a market cap of CAD$98.363 million!
AGN is currently receiving zero value for its significant DMT intellectual property!
Past performance is not an indicator of future returns. NIA is not an investment advisor and does not provide investment advice. Always do your own research and make your own investment decisions. This message is not a solicitation or recommendation to buy, sell, or hold securities. NIA has received compensation from AGN of US$100,000 cash for a twelve-month marketing contract. This message is meant for informational and educational purposes only and does not provide investment advice.
Preparing Americans for Hyperinflation
